Tony Wood, GSK’s chief scientific officer, said: “We are excited by this new data which shows that a single dose of Arexvy ...

RSV vaccines have reportedly fallen since U.S. regulators narrowed the recommended age range and frequency for the shots.

The vaccine demonstrated efficacy across different respiratory syncytial virus (RSV) subtypes in older adults between the ...

The protection also held across different strains, for people in their 70s, and for those with underlying medical conditions.

Zantac settlement should ease investors’ nervousness but long-standing concerns about drugmaker’s pipeline remain ...

A study of long-term care facilities found residents with penicillin allergies were 95% less likely to receive beta-lactam ...

GSK has agreed to pay $2.2bn to settle about 80,000 Zantac lawsuits in the US. In a statement released after the close of ...

On a similar front, 3% of U.S. high school students surveyed in 2023 identified as transgender, and 25% of transgender ...

As the days grow cooler, families across Utah are reminded that respiratory viruses, particularly Respiratory Syncytial Virus ...

EDP-323 is an investigational inhibitor of Respiratory Syncytial Virus (RSV), currently showing promising results in Phase 2a ...

The RSV vaccine is unequivocally recommended for adults who are residents in skilled nursing and assisted living facilities.

Thursday reported positive topline results from the Phase 3 TALAPRO-2 study of Talzenna in combination with Xtandi ...